Research & Literature

Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection.

Beuschlein F, Weigel J, Saeger W, et al.

The Journal of clinical endocrinology and metabolism 2015; (100(3)):841-9 doi:10.1210/jc.2014-3182.

Diagnosis, treatment and outcome of adrenocortical cancer.

Mihai R

The British journal of surgery 2015; (102(4)):291-306 doi:10.1002/bjs.9743.

The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study.

Smith AB, Butow P, Olver I, et al.

Journal of cancer survivorship : research and practice 2016; (10(2)):223-33 doi:10.1007/s11764-015-0468-5.

Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence.

Amini N, Margonis GA, Kim Y, et al.

Annals of surgical oncology 2016; (23(1)):126-33 doi:10.1245/s10434-015-4810-y.

Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes.

Margonis GA, Kim Y, Prescott JD, et al.

Annals of surgical oncology 2016; (23(1)):134-41 doi:10.1245/s10434-015-4803-x.

Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study.

Libé R, Borget I, Ronchi CL, et al.

Annals of oncology : official journal of the European Society for Medical Oncology 2015; (26(10)):2119-25 doi:10.1093/annonc/mdv329.

Comparison of the methods for measuring the Ki-67 labeling index in adrenocortical carcinoma: manual versus digital image analysis.

Yamazaki Y, Nakamura Y, Shibahara Y, et al.

Human pathology 2016; (53()):41-50.

Procedural and clinical outcomes of percutaneous adrenal biopsy in a high-risk population for adrenal malignancy.

Delivanis DA, Erickson D, Atwell TD, et al.

Clinical endocrinology 2016; (85(5)):710-716 doi:10.1111/cen.13117.

DIAGNOSIS OF ENDOCRINE DISEASE: The diagnostic performance of adrenal biopsy: a systematic review and meta-analysis.

Bancos I, Tamhane S, Shah M, et al.

European journal of endocrinology 2016; (175(2)):R65-80 doi:10.1530/EJE-16-0297.

Dyslipidemia causes overestimation of plasma mitotane measurements.

Paci A, Hescot S, Seck A, et al.

Endocrinology, diabetes & metabolism case reports 2016; (2016()):150135 doi:10.1530/EDM-15-0135.

Prevalence and correlates of fear of recurrence among adolescent and young adult versus older adult post-treatment cancer survivors.

Shay LA, Carpentier MY, Vernon SW

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2016; (24(11)):4689-96 doi:10.1007/s00520-016-3317-9.

Clinical Score Predicting Long-Term Survival after Repeat Resection for Recurrent Adrenocortical Carcinoma.

Tran TB, Maithel SK, Pawlik TM, et al.

Journal of the American College of Surgeons 2016; (223(6)):794-803 doi:10.1016/j.jamcollsurg.2016.08.568.

Minimally Invasive Resection of Adrenocortical Carcinoma: a Multi-Institutional Study of 201 Patients.

Lee CW, Salem AI, Schneider DF, et al.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2017; (21(2)):352-362 doi:10.1007/s11605-016-3262-4.

Surgery for recurrent adrenocortical carcinoma: A multicenter retrospective study.

Simon G, Pattou F, Mirallié E, et al.

Surgery 2017; (161(1)):249-256 doi:10.1016/j.surg.2016.08.058.

Immediate versus modified release hydrocortisone in mitotane-treated patients with adrenocortical cancer.

Weigel M, Hahner S, Sherlock M, et al.

Clinical endocrinology 2017; (86(4)):499-505 doi:10.1111/cen.13302.

Therapeutic drug monitoring of mitotane: Analytical assay and patient follow-up.

Feliu C, Cazaubon Y, Guillemin H, et al.

Biomedical chromatography : BMC 2017; (31(11)) doi:10.1002/bmc.3993.

Surgical treatment of adrenal carcinoma.

Gaujoux S, Weinandt M, Bonnet S, et al.

Journal of visceral surgery 2017; (154(5)):335-343 doi:10.1016/j.jviscsurg.2017.06.010.

Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma.

Reimondo G, Puglisi S, Zaggia B, et al.

European journal of endocrinology 2017; (177(4)):361-367 doi:10.1530/EJE-17-0452.

[ADRENOCORTICAL CARCINOMA].

Kranjčević K

Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti 2016; (70(4-5)):315-8.

[Surgical strategies for non-metastatic adrenocortical carcinoma].

Rayes N, Quinkler M, Denecke T

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 2018; (89(6)):434-439 doi:10.1007/s00104-017-0582-1.

Laparoscopic Versus Open Adrenalectomy for Localized/Locally Advanced Primary Adrenocortical Carcinoma (ENSAT I-III) in Adults: Is Margin-Free Resection the Key Surgical Factor that Dictates Outcome? A Review of the Literature.

Mpaili E, Moris D, Tsilimigras DI, et al.

Journal of laparoendoscopic & advanced surgical techniques. Part A 2018; (28(4)):408-414 doi:10.1089/lap.2017.0546.

Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma.

Megerle F, Herrmann W, Schloetelburg W, et al.

The Journal of clinical endocrinology and metabolism 2018; (103(4)):1686-1695 doi:10.1210/jc.2017-02591.

Impact of Micro- and Macroscopically Positive Surgical Margins on Survival after Resection of Adrenocortical Carcinoma.

Anderson KL, Adam MA, Thomas SM, et al.

Annals of surgical oncology 2018; (25(5)):1425-1431 doi:10.1245/s10434-018-6398-5.

Adrenocortical Carcinoma with Hypercortisolism.

Puglisi S, Perotti P, Pia A, et al.

Endocrinology and metabolism clinics of North America 2018; (47(2)):395-407 doi:10.1016/j.ecl.2018.02.003.

European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors

Fassnacht M, Dekkers OM, Else T, et al.

European journal of endocrinology 2018; (179(4)):G1-G46 doi:10.1530/EJE-18-0608.

An Interesting Case of Hepatic Adrenocortical Carcinoma.

Permana H, Darmawan G, Ritonga E, et al.

Acta medica Indonesiana 2018; (50(3)):257-259.

Longitudinal patterns of recurrence in patients with adrenocortical carcinoma.

Glenn JA, Else T, Hughes DT, et al.

Surgery 2019; (165(1)):186-195 doi:10.1016/j.surg.2018.04.068.

Role of Mitotane in Adrenocortical Carcinoma - Review and State of the art.

Paragliola RM, Torino F, Papi G, et al.

European endocrinology 2018; (14(2)):62-66 doi:10.17925/EE.2018.14.2.62.

Giant nonfunctioning adrenal tumors: two case reports and review of the literature.

Chatzoulis G, Passos I, Bakaloudi DR, et al.

Journal of medical case reports 2018; (12(1)):335 doi:10.1186/s13256-018-1876-8.

Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.

Calabrese A, Basile V, Puglisi S, et al.

European journal of endocrinology 2019; (180(6)):387-396.

A method for the minimally invasive drug monitoring of mitotane by means of volumetric absorptive microsampling for a home-based therapeutic drug monitoring.

Friedl B, Kurlbaum M, Kroiss M, et al.

Analytical and bioanalytical chemistry 2019; (411(17)):3951-3962 doi:10.1007/s00216-019-01868-1.

Aldosterone-Secreting Adrenocortical Carcinoma Presenting With Cardiac Arrest.

Zern NK, Eaton KD, Roth MY

Journal of the Endocrine Society 2019; (3(9)):1678-1681 doi:10.1210/js.2019-00092.

Estrogen-secreting adrenocortical carcinoma.

Jeong Y, Cho SC, Cho HJ, et al.

Yeungnam University journal of medicine 2019; (36(1)):54-58 doi:10.12701/yujm.2019.00017.

Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma.

Chortis V, Bancos I, Nijman T, et al.

The Journal of clinical endocrinology and metabolism 2020; (105(3)) doi:10.1210/clinem/dgz141.

Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma.

Poirier J, Gagnon N, Terzolo M, et al.

Cancers 2020; (12(3)) doi:10.3390/cancers12030639.

A rare case of oncocytic adrenocortical carcinoma clinically presented as an incidentaloma.

Harada K, Yasuda M, Nakano Y, et al.

Endocrine journal 2020; (67(8)):883-888 doi:10.1507/endocrj.EJ20-0024.

Surgery for adrenocortical carcinoma: When and how?

Sinclair TJ, Gillis A, Alobuia WM, et al.

Best practice & research. Clinical endocrinology & metabolism 2020; (34(3)):101408 doi:10.1016/j.beem.2020.101408.

Minimally Invasive Versus Open Adrenalectomy in Patients with Adrenocortical Carcinoma: A Meta-analysis.

Hu X, Yang WX, Shao YX, et al.

Annals of surgical oncology 2020; (27(10)):3858-3869 doi:10.1245/s10434-020-08454-1.

Oligometastatic adrenocortical carcinoma: the role of image-guided thermal ablation.

Veltri A, Basile D, Calandri M, et al.

European radiology 2020; (30(12)):6958-6964 doi:10.1007/s00330-020-07019-w.

Guidance for the prevention and emergency management of adult patients with adrenal insufficiency.

Simpson H, Tomlinson J, Wass J, et al.

Clinical medicine (London, England) 2020; (20(4)):371-378 doi:10.7861/clinmed.2019-0324.

Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study.

Bancos I, Taylor AE, Chortis V, et al.

The lancet. Diabetes & endocrinology 2020; (8(9)):773-781 doi:10.1016/S2213-8587(20)30218-7.

Metabolic and hormonal side effects of mitotane treatment for adrenocortical carcinoma: A retrospective study in 50 Danish patients.

Vikner ME, Krogh J, Daugaard G, Andreassen M

Clinical endocrinology 2021; (94(2)):141-149 doi:10.1111/cen.14345.

Data set for reporting of carcinoma of the adrenal cortex: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting.

Giordano TJ, Berney D, de Krijger RR, et al.

Human pathology 2021; (110()):50-61 doi:10.1016/j.humpath.2020.10.001.

Advanced adrenocortical carcinoma successfully treated with gemcitabine plus capecitabine as second-line chemotherapy.

Yamamoto A, Nakai Y, Oka T, et al.

IJU case reports 2020; (3(6)):270-273 doi:10.1002/iju5.12214.

Operative intervention for recurrence of adrenocortical carcinoma: A single-center experience.

Zhang F, Liu Z, Liang J, et al.

Surgery 2021; (169(5)):1131-1138 doi:10.1016/j.surg.2020.10.041.

Aldosterone-Producing Adrenocortical Carcinoma with Co-Secretion of Cortisol and Estradiol: A Case Report.

Lazaro K, Adorable-Wagan P

Journal of the ASEAN Federation of Endocrine Societies 2018; (33(1)):57-62 doi:10.15605/jafes.033.01.10.

Adrenal insufficiency.

Husebye ES, Pearce SH, Krone NP, Kämpe O

Lancet (London, England) 2021; (397(10274)):613-629 doi:10.1016/S0140-6736(21)00136-7.

Reassessing the impact of tumor size on operative approach in adrenocortical carcinoma.

Hue JJ, Bingmer K, Zhao H, et al.

Journal of surgical oncology 2021; (123(5)):1238-1245 doi:10.1002/jso.26418.

Delayed Identification of Adolescent Adrenal Cortical Carcinoma Initially Diagnosed as Polycystic Ovary Syndrome.

Ziqin L, Yurui W, Xiaobo C, et al.

Journal of pediatric and adolescent gynecology 2021; (34(5)):764-767 doi:10.1016/j.jpag.2021.03.004.

American Association of Clinical Endocrinology Disease State Clinical Review on the Evaluation and Management of Adrenocortical Carcinoma in an Adult: a Practical Approach.

Kiseljak-Vassiliades K, Bancos I, Hamrahian A, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2020; (26(11)):1366-1383 doi:10.4158/DSCR-2020-0567.

Adrenal and Hepatic Venous Sampling in a Case of Aldosterone-Producing Adrenocortical Carcinoma with Hepatic Metastasis.

Sugiyama T, Sasahara Y, Sasano H, Hayakawa E

Case reports in endocrinology 2021; (2021()):5584198 doi:10.1155/2021/5584198.

Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience.

Uchihara M, Tanioka M, Kojima Y, et al.

International journal of clinical oncology 2021; (26(12)):2275-2281 doi:10.1007/s10147-021-02021-8.

How to Differentiate Benign from Malignant Adrenocortical Tumors?

Viëtor CL, Creemers SG, van Kemenade FJ, et al.

Cancers 2021; (13(17)) doi:10.3390/cancers13174383.

Metabolic and Endocrine Toxicities of Mitotane: A Systematic Review.

Bianchini M, Puliani G, Chiefari A, et al.

Cancers 2021; (13(19)) doi:10.3390/cancers13195001.

S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study.

Elhassan YS, Altieri B, Berhane S, et al.

European journal of endocrinology 2021; (186(1)):25-36.

Adrenocortical Carcinoma: The Value of Lymphadenectomy.

Tseng J, DiPeri T, Chen Y, et al.

Annals of surgical oncology 2022; (29(3)):1965-1970 doi:10.1245/s10434-021-11051-5.

Impact of Lymphadenectomy on the Oncologic Outcome of Patients with Adrenocortical Carcinoma-A Systematic Review and Meta-Analysis.

Hendricks A, Müller S, Fassnacht M, et al.

Cancers 2022; (14(2)) doi:10.3390/cancers14020291.

Adrenocortical carcinoma with multiple liver metastases controlled by bland transarterial embolization and surgery resulting in long-term survival.

Watanabe K, Kodama Y, Sakurai Y, et al.

Radiology case reports 2022; (17(4)):1095-1098 doi:10.1016/j.radcr.2022.01.052.

[Emergency card, emergency medication, and information leaflet for the prevention and treatment of adrenal crisis (Addison crisis): an Austrian consensus document].

Pilz S, Krebs M, Bonfig W, et al.

Journal fur klinische Endokrinologie und Stoffwechsel 2022; (15(1)):5-27 doi:10.1007/s41969-022-00155-2.

Diagnostic dilemmas: a multi-institutional retrospective analysis of adrenal incidentaloma pathology based on radiographic size.

Zekan D, King RS, Hajiran A, et al.

BMC urology 2022; (22(1)):73 doi:10.1186/s12894-022-01024-5.

Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen.

Turla A, Laganà M, Grisanti S, et al.

Endocrine 2022; (77(3)):438-443 doi:10.1007/s12020-022-03075-y.

ENDOCRINE TUMOURS: Our experience with the management of patients with non-metastatic adrenocortical carcinoma.

Terzolo M, Fassnacht M

European journal of endocrinology 2022; (187(3)):R27-R40 doi:10.1530/EJE-22-0260.

The effect of psychological interventions on fear of cancer recurrence in breast cancer survivors: A systematic review and meta-analysis.

Lyu MM, Siah RC, Lam ASL, Cheng KKF

Journal of advanced nursing 2022; (78(10)):3069-3082 doi:10.1111/jan.15321.

Minimally Invasive Surgery for Resectable Adrenocortical Carcinoma: A Nationwide Analysis.

Delman AM, Turner KM, Griffith A, et al.

The Journal of surgical research 2022; (279()):200-207 doi:10.1016/j.jss.2022.04.078.

[Are there still indications for open adrenalectomy?]

Holzer K, Bartsch DK

Chirurgie (Heidelberg, Germany) 2022; (93(9)):856-860 doi:10.1007/s00104-022-01678-9.

Prognostic Factors in Advanced Adrenocortical Carcinoma: Summary of a National Referral Center's 20 years of Experience.

Arnon J, Grozinsky-Glasberg S, Oleinikov K, et al.

Journal of the Endocrine Society 2022; (6(9)):bvac112 doi:10.1210/jendso/bvac112.

Diagnosis of Adrenocortical Carcinoma with Hypercortisolism in a Patient Presenting with Hypokalemic Metabolic Alkalosis.

Khan O, Raashid S, Hashim M, et al.

Journal of community hospital internal medicine perspectives 2022; (12(5)):114-118 doi:10.55729/2000-9666.1108.

Open Versus Laparoscopic Surgery in the Management of Adrenocortical Carcinoma: A Systematic Review and Meta-analysis.

Nakanishi H, Miangul S, Wang R, et al.

Annals of surgical oncology 2023; (30(2)):994-1005 doi:10.1245/s10434-022-12711-w.

A Systematic Review of Published Clinical Trials in the Systemic Treatment of Adrenocortical Carcinoma: An Initiative Led on Behalf of the Global Society of Rare Genitourinary Tumors.

Padua TC, Marandino L, Raggi D, et al.

Clinical genitourinary cancer 2023; (21(1)):1-7 doi:10.1016/j.clgc.2022.10.011.

Treatment of adrenocortical carcinoma: oncological and endocrine outcomes.

Brönimann S, Garstka N, Remzi M

Current opinion in urology 2023; (33(1)):50-58 doi:10.1097/MOU.0000000000001045.

Efficacy and safety of radiation therapy in advanced adrenocortical carcinoma.

Kimpel O, Schindler P, Schmidt-Pennington L, et al.

British journal of cancer 2023; (128(4)):586-593 doi:10.1038/s41416-022-02082-0.

The management of postoperative disease recurrence in patients with adrenocortical carcinoma: a retrospective study in 106 patients.

Calabrese A, Puglisi S, Borin C, et al.

European journal of endocrinology 2023; (188(1)) doi:10.1093/ejendo/lvad002.

Central Hypothyroidism is Frequent During Mitotane Therapy in Adrenocortical Cancer Patients: Prevalence and Timeline.

Poirier J, Godemel S, Mourot A, et al.

The Journal of clinical endocrinology and metabolism 2023; (108(9)):2336-2342 doi:10.1210/clinem/dgad115.

Adrenocortical Carcinoma: Role of Adjuvant and Neoadjuvant Therapy.

Kenney L, Hughes M

Surgical oncology clinics of North America 2023; (32(2)):279-287 doi:10.1016/j.soc.2022.10.005.

Simplified urinary steroid profiling by LC-MS as diagnostic tool for malignancy in adrenocortical tumors.

Vogg N, Müller T, Floren A, et al.

Clinica chimica acta; international journal of clinical chemistry 2023; (543()):117301 doi:10.1016/j.cca.2023.117301.

[Guidelines of the French National ENDOCAN-COMETE, Association of Endocrine Surgery, Society of Urology for the management of adrenocortical carcinoma].

Libé R, Haissaguerre M, Renaudin K, et al.

Bulletin du cancer 2023; (110(6)):707-730 doi:10.1016/j.bulcan.2023.03.015.

European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors.

Fassnacht M, Tsagarakis S, Terzolo M, et al.

European journal of endocrinology 2023; (189(1)):G1-G42 doi:10.1093/ejendo/lvad066.

Adrenal Neoplasms: Lessons from Adrenal Multidisciplinary Tumor Boards.

Chung R, Garratt J, Remer EM, et al.

Radiographics : a review publication of the Radiological Society of North America, Inc 2023; (43(7)):e220191 doi:10.1148/rg.220191.

Adrenocortical cancer recurrence following initial transcutaneous biopsy: a rare demonstration of needle tract seeding.

Younes N, Bourdeau I, Olney H, et al.

Endocrine oncology (Bristol, England) 2021; (1(1)):K7-K12 doi:10.1530/EO-21-0031.

Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma.

Gagnon N, Bernard S, Paquette M, et al.

Endocrine oncology (Bristol, England) 2022; (2(1)):1-8 doi:10.1530/EO-21-0021.

Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study.

Terzolo M, Fassnacht M, Perotti P, et al.

The lancet. Diabetes & endocrinology 2023; (11(10)):720-730 doi:10.1016/S2213-8587(23)00193-6.

Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study.

Mormando M, Galiè E, Bianchini M, et al.

Frontiers in oncology 2023; (13()):1222002 doi:10.3389/fonc.2023.1222002.

Adrenocortical carcinoma: Diagnosis, prognostic classification and treatment of localized and advanced disease.

Libé R, Huillard O

Cancer treatment and research communications 2023; (37()):100759 doi:10.1016/j.ctarc.2023.100759.

Advances in translational research of the rare cancer type adrenocortical carcinoma.

Ghosh C, Hu J, Kebebew E

Nature reviews. Cancer 2023; (23(12)):805-824 doi:10.1038/s41568-023-00623-0.

The effect of hormonal secretion on survival in adrenocortical carcinoma: A multi-center study.

Sada A, Foster TR, Al-Ward R, et al.

Surgery 2024; (175(1)):80-89 doi:10.1016/j.surg.2023.04.070.

Hypertriglyceridemia and its impact on mitotane monitoring in adrenocortical carcinoma.

Martens S, Lapauw B

Endocrinology, diabetes & metabolism case reports 2023; (2023(4)).

Current Evidence on Local Therapies in Advanced Adrenocortical Carcinoma.

Kimpel O, Dischinger U, Altieri B, et al.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2024; (56(1)):91-98 doi:10.1055/a-2209-6022.

Recovery of adrenal function after stopping mitotane in patients with adrenocortical carcinoma.

Altieri B, Kimpel O, Megerle F, et al.

European journal of endocrinology 2024; (190(2)):139-150 doi:10.1093/ejendo/lvae007.

Early Detection of Recurrence and Progress Using Serum Steroid Profiling by LC-MS/MS in Patients with Adrenocortical Carcinoma.

Kimpel O, Altieri B, Dischinger U, et al.

Metabolites 2023; (14(1)) doi:10.3390/metabo14010020.

The Value of Local Therapies in Advanced Adrenocortical Carcinoma.

Kimpel O, Altieri B, Laganà M, et al.

Cancers 2024; (16(4)) doi:10.3390/cancers16040706.

Diagnosis and management of secondary adrenal crisis.

Martel-Duguech L, Poirier J, Bourdeau I, Lacroix A

Reviews in endocrine & metabolic disorders 2024; (25(3)):619-637 doi:10.1007/s11154-024-09877-x.

Texture analysis can predict response to etoposide-doxorubicin-cisplatin in patients with adrenocortical carcinoma.

Crimì F, Turatto F, D'Alessandro C, et al.

Journal of endocrinological investigation 2025; (48(3)):711-720 doi:10.1007/s40618-024-02476-2.

Survival impact of treatment utilization and margin status after resection of adrenocortical carcinoma.

Memeh K, Abou Azar S, Afolaranmi O, Vaghaiwalla TM

American journal of surgery 2025; (239()):115999 doi:10.1016/j.amjsurg.2024.115999.

Scanxiety and Fear of Recurrence in Young Adult Female Breast and Gynaecological Cancer Survivors: Investigating Shared Mechanisms.

Patel DS, Webster SN, Dowling EJ, et al.

Psycho-oncology 2024; (33(12)):e70050 doi:10.1002/pon.70050.

Treatment and Prevention of Adrenal Crisis and Family Education

Çamtosun E, Sangün Ö

Journal of clinical research in pediatric endocrinology 2025; (17(Suppl 1)):80-92 doi:10.4274/jcrpe.galenos.2024.2024-6-12-S.

Efficacy and Safety of Radiotherapy and Systemic Treatments in Adrenocortical Carcinoma: Systematic Review and Meta-Analysis.

Pfeffer A, Beke N, Bakó D, et al.

The Journal of clinical endocrinology and metabolism 2025; (110(12)):3599-3608 doi:10.1210/clinem/dgaf457.

External validation of the S-GRAS score for predicting recurrence in patients with adrenocortical carcinoma: implications for adjuvant mitotane therapy.

Jimenez-Fonseca P, Álvarez-Escola C, Ballester Navarro I, et al.

European journal of endocrinology 2025; (193(2)):320-328 doi:10.1093/ejendo/lvaf171.

Mitotane-Induced Endocrine Alterations in Children with Adrenocortical Carcinoma: Clinical Implications from a 20-Year Retrospective Study.

Tuli G, Munarin J, Vallero SG, et al.

Children (Basel, Switzerland) 2025; (12(8)) doi:10.3390/children12081031.

Diagnosis and grading of adrenal cortical carcinoma.

Vocino Trucco G, Duregon E, Papotti M, Volante M

Virchows Archiv : an international journal of pathology 2026; (488(1)):193-210 doi:10.1007/s00428-025-04278-0.

Comparative Efficacy of Psychosocial Interventions on Fear of Cancer Recurrence: A Network Meta-Analysis.

Qian J, Sun S, Wang M, Xue Q

Cancer nursing 2026; doi:10.1097/NCC.0000000000001565.

CT and MRI in the Characterization and Preoperative Assessment of Adrenocortical Carcinoma: Current Concepts and Perspectives.

Barat M, Gaillard M, Dohan A, et al.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes 2026; 8465371261438317 doi:10.1177/08465371261438317.

Adjuvant mitotane in low-risk adrenocortical carcinoma: A reconstructed IPD analysis of the ADIUVO randomized and observational studies.

Flauto F, Neola G, Vitale F, Damiano V

Critical reviews in oncology/hematology 2026; (223()):105346 doi:10.1016/j.critrevonc.2026.105346.

Patient Experience of Adrenocortical Carcinoma: Views from a Patient, His Physician and a Patient Association.

Büdenbender M, Heitz-Lamy C, Fassnacht M

Advances in therapy 2026; doi:10.1007/s12325-026-03718-w.